Repository logo
 
Publication

Real-World Outcomes of Anti-VEGF Treatment for Retinal Vein Occlusion in Portugal

2017-11-08Journal article Open access
Simple item page
dc.contributor.authorVaz-Pereira, S
dc.contributor.authorMarques, IP
dc.contributor.authorMatias, J
dc.contributor.authorMira, F
dc.contributor.authorRibeiro, L
dc.contributor.authorFlores, R
dc.date.accessioned2021-02-05T17:49:38Z
dc.date.available2021-02-05T17:49:38Z
dc.date.issued2017-11-08
dc.description.abstractPurpose: Retinal vein occlusion (RVO) is an important cause of visual disability in the modern world. We aim to evaluate the real-world outcomes of patients with RVO treated with anti-vascular endothelial growth factor (VEGF) in Portugal. Methods: We performed a retrospective, observational, multicenter study including 8 centers across Portugal and 200 patients treated with either ranibizumab or bevacizumab. Data were collected at 3 time points: time of diagnosis (0 time point) and 6 and 12 months after initiating treatment. Demographic and clinical data were collected. Results: Median visual acuity (VA) and central macular thickness (CMT) improved in the branch RVO (BRVO), central RVO (CRVO), bevacizumab, and ranibizumab groups at 6 and 12 months compared to baseline, with CMT improving further only in the CRVO and ranibizumab groups between 6 and 12 months (p = 0.002 and p = 0.001, respectively). The CMT was lower in the ranibizumab group compared to the bevacizumab group both at 6 and 12 months (p<0.02). Median CMT improved in both the good and poor baseline VA groups at 6 and 12 months compared to baseline (p<0.001). Median VA only improved for the group with poor baseline VA at 6 and 12 months of follow-up (p<0.001). Regression analysis identified several baseline variables as predictors of visual outcomes at 6 and 12 months, with different results depending on the analyzed group. Conclusions: Both treatments were effective, although less effective than results reported in clinical trials. The morphologic response was better with ranibizumab compared to bevacizumab, although functionally there were no differences.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationEur J Ophthalmol. 2017 Nov 8;27(6):756-761.pt_PT
dc.identifier.doi10.5301/ejo.5000943pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/3567
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherWichtig Publishingpt_PT
dc.subjectAdultpt_PT
dc.subjectAgedpt_PT
dc.subjectAged, 80 and overpt_PT
dc.subjectAngiogenesis Inhibitorspt_PT
dc.subjectBevacizumabpt_PT
dc.subjectFemalept_PT
dc.subjectHumanspt_PT
dc.subjectIntravitreal Injectionspt_PT
dc.subjectMacula Luteapt_PT
dc.subjectMacular Edemapt_PT
dc.subjectMalept_PT
dc.subjectMiddle Agedpt_PT
dc.subjectPortugalpt_PT
dc.subjectRanibizumabpt_PT
dc.subjectRetinal Vein Occlusionpt_PT
dc.subjectRetrospective Studiespt_PT
dc.subjectVascular Endothelial Growth Factor Apt_PT
dc.subjectVisual Acuitypt_PT
dc.subjectHSAC OFTpt_PT
dc.titleReal-World Outcomes of Anti-VEGF Treatment for Retinal Vein Occlusion in Portugalpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage761pt_PT
oaire.citation.issue6pt_PT
oaire.citation.startPage756pt_PT
oaire.citation.titleEuropean Journal of Ophthalmologypt_PT
oaire.citation.volume27pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Europ J Opthalm 2017.pdf
Size:
625.89 KB
Format:
Adobe Portable Document Format
Download

Collections

OFT - Artigos